Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03850067
Title A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celgene
Indications

lung small cell carcinoma

Therapies

Carboplatin + CC-90011 + Etoposide

CC-90011 + Cisplatin + Etoposide

Nivolumab

Age Groups: adult | senior
Covered Countries ITA | FRA | ESP


No variant requirements are available.